EUVIMEDEUVIMED entdecken
Open Access

Evaluation of 177 Lu-PSMA-617 SPECT/CT Quantitation as a Response Biomarker Within a Prospective 177 Lu-PSMA-617 and NOX66 Combination Trial (LuPIN)

Sarennya Pathmanandavel, Megan Crumbaker, Bao Ho, Andrew O Yam, Peter Wilson, Remy Niman, Maria Ayers, Shikha Sharma, Adam Hickey, Peter Eu, Martin Stockler, Andrew J Martin und 3 weitere

Journal of Nuclear Medicine · 2023-02 · 64 (2) · 221-226

DOI: 10.2967/jnumed.122.264398 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Nuclear Medicine, online erschienen am 25.08.2022. Verfasst von Sarennya Pathmanandavel und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Theranostics and Nuclear Medicine, St. Vincent's Hospital, Sydney, New South Wales, Australia. Hauptthemen laut MEDLINE: Prostate-Specific Antigen, Prostatic Neoplasms, Castration-Resistant. Die Arbeit wurde bisher 67-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostate-Specific AntigenProstatic Neoplasms, Castration-ResistantMaleHumansTreatment OutcomePositron Emission Tomography Computed TomographyProspective StudiesRadiopharmaceuticalsDipeptidesHeterocyclic Compounds, 1-RingSingle Photon Emission Computed Tomography Computed TomographyLutetium

Stichwörter der Autor:innen

SPECTlutetium-PSMAmetastatic prostate cancerresponse biomarker

Substanzen

PSMA-617Prostate-Specific AntigenRadiopharmaceuticalsDipeptidesHeterocyclic Compounds, 1-RingLutetium

Autor:innen und Institutionen

  • Department of Theranostics and Nuclear Medicine, St. Vincent's Hospital, Sydney, New South Wales, Australia.
  • Kinghorn Cancer Centre, St. Vincent's Hospital, Sydney, New South Wales, Australia.
  • Garvan Institute of Medical Research, Sydney, New South Wales, Australia.
  • St. Vincent's Clinical School, University of New South Wales, Sydney, New South Wales, Australia.
  • MIM Software, Inc., Cleveland, Ohio.
  • Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; and.

Zitieren

APA

Pathmanandavel, S., Crumbaker, M., Ho, B., Yam, A. O., Wilson, P., Niman, R., Ayers, M., Sharma, S., Hickey, A., Eu, P., Stockler, M., Martin, A. J., Joshua, A. M., Nguyen, A., & Emmett, L. (2023). Evaluation of 177 Lu-PSMA-617 SPECT/CT Quantitation as a Response Biomarker Within a Prospective 177 Lu-PSMA-617 and NOX66 Combination Trial (LuPIN). Journal of Nuclear Medicine, 64(2), 221-226. https://doi.org/10.2967/jnumed.122.264398

Vancouver

Pathmanandavel S, Crumbaker M, Ho B, Yam AO, Wilson P, Niman R, et al. Evaluation of 177 Lu-PSMA-617 SPECT/CT Quantitation as a Response Biomarker Within a Prospective 177 Lu-PSMA-617 and NOX66 Combination Trial (LuPIN). Journal of Nuclear Medicine. 2023;64(2):221-226. doi:10.2967/jnumed.122.264398

BibTeX
@article{Pathmanandavel2023,
  author = {Pathmanandavel, Sarennya and Crumbaker, Megan and Ho, Bao and Yam, Andrew O and Wilson, Peter and Niman, Remy and Ayers, Maria and Sharma, Shikha and Hickey, Adam and Eu, Peter and Stockler, Martin and Martin, Andrew J and Joshua, Anthony M and Nguyen, Andrew and Emmett, Louise},
  title = {Evaluation of 177 Lu-PSMA-617 SPECT/CT Quantitation as a Response Biomarker Within a Prospective 177 Lu-PSMA-617 and NOX66 Combination Trial (LuPIN)},
  journal = {Journal of Nuclear Medicine},
  year = {2023},
  volume = {64},
  number = {2},
  pages = {221--226},
  doi = {10.2967/jnumed.122.264398}
}
Kostenlos starten →